Nexstim Plc: Managers’ Transactions, Järnefelt
27 maj, 10:45
Company Announcement, Helsinki, 27 May 2025 at 11:45 AM (EEST)
Nexstim Plc: Managers’ Transactions, Järnefelt
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows:
Person subject to the notification requirement
Name: Järnefelt, Gustaf
Position: Other senior manager
Issuer: Nexstim Plc
LEI: 743700S7ZI0LNMHZ6Y27
Notification type: INITIAL NOTIFICATION
Reference number: 743700S7ZI0LNMHZ6Y27_20250526150817_7
____________________________________________
Transaction date: 2025-05-22
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 14288 Unit price: 0.00 EUR
Aggregated transactions
(1): Volume: 14288 Volume weighted average price: 0.00 EUR
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
AttachmentsNexstim Plc_Company announcement_Managers transactions_27052025_J�rnefelt_EN.pdf
Ämnen i artikeln
Nexstim Plc: Managers’ Transactions, Järnefelt
27 maj, 10:45
Company Announcement, Helsinki, 27 May 2025 at 11:45 AM (EEST)
Nexstim Plc: Managers’ Transactions, Järnefelt
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows:
Person subject to the notification requirement
Name: Järnefelt, Gustaf
Position: Other senior manager
Issuer: Nexstim Plc
LEI: 743700S7ZI0LNMHZ6Y27
Notification type: INITIAL NOTIFICATION
Reference number: 743700S7ZI0LNMHZ6Y27_20250526150817_7
____________________________________________
Transaction date: 2025-05-22
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 14288 Unit price: 0.00 EUR
Aggregated transactions
(1): Volume: 14288 Volume weighted average price: 0.00 EUR
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
AttachmentsNexstim Plc_Company announcement_Managers transactions_27052025_J�rnefelt_EN.pdf
Ämnen i artikeln
Analys
-992x558.jpg&w=3840&q=75)
Danmarks nationaldag
-992x558.png&w=3840&q=75)
Fondernas placeringar
-992x558.jpg&w=3840&q=75)
Inflationen
-992x558.jpg&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
Investmentbolag
Analys
Danmarks nationaldag
Fondernas placeringar
Inflationen
Investmentbolag
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
